Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 0.52 |
| ▸ | CA2 | P00918 | 12/20 | 0.52 |
| ▸ | CA9 | Q16790 | 10/20 | 0.52 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA7 | P43166 | 3/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.52 |
| ▸ | CA3 | P07451 | 2/20 | 0.52 |
| ▸ | CA4 | P22748 | 2/20 | 0.52 |
| ▸ | CA6 | P23280 | 2/20 | 0.52 |
| ▸ | CA5A | P35218 | 2/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5857046 | 1.00 | CA1 (0.52) | CA1CA2CA9CA12CA7 | |
| SCHEMBL27822399 | 1.00 | CA1 (0.52) | CA1CA2CA9CA12CA7 | |
| SCHEMBL28600381 | 0.98 | CA1 (0.50) | CA1CA2CA9CA12CA7 | |
| SCHEMBL28405693 | 0.98 | CA1 (0.50) | CA1CA2CA9CA12CA7 | |
| SCHEMBL27245305 | 0.98 | CA1 (0.50) | CA1CA2CA9CA12CA7 | |
| SCHEMBL9418535 | 0.98 | CA1 (0.50) | CA1CA2CA9CA12CA7 | |
| SCHEMBL30893 | 0.98 | CA1 (0.50) | CA1CA2CA9CA12CA7 | |
| Formaldehyde SCHEMBL5810342 | 0.96 | CA1 (0.48) | CA1CA2CA9CA12CA7 | |
| SCHEMBL1419888 | 0.96 | CA1 (0.48) | CA1CA2CA9CA12CA7 | |
| Ammonia Solution, Strong SCHEMBL1646991 | 0.96 | CA1 (0.48) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112545911-A | Compositions, care agents, uses and methods for reducing skin irritation | 华熙生物科技股份有限公司 | 2021-03-26 | — | — | CN | claimed |
| CN-102504078-A | Method for preparing electrolyte-resisting thickening agent | ZHEJIANG JINGYE BIOCHEMICAL CO LTD | 2012-06-20 | — | — | CN | claimed |
| US-20240238303-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | ENALARE THERAPEUTICS INC (US) | 2024-07-18 | — | — | US | disclosed |
| EP-4398863-A1 | THERMO-SENSITIVE COMPOSITION AND METHOD FOR PREPARATION THEREOF | BASF SE (DE) | 2024-07-17 | — | — | EP | disclosed |
| US-20240226007-A1 | NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | Sovida Solutions Ltd. (GB) | 2024-07-11 | — | — | US | disclosed |
| US-12016939-B2 | Skin treatment methods and compositions for transdermal delivery of active agents | TOPIX PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240108556-A1 | SCAR TREATMENT COMPOSITION | TOPIX PHARMACEUTICALS, INC. | 2024-04-04 | — | — | US | disclosed |
| US-20240091122-A1 | Growth Factor Formulation | TOPIX PHARMACEUTICALS, INC. | 2024-03-21 | — | — | US | disclosed |
| EP-4333807-A1 | NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | Sovida Solutions Ltd. (GB) | 2024-03-13 | — | — | EP | disclosed |
| EP-4333852-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | Enalare Therapeutics Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20240075112-A1 | SCAR TREATMENT COMPOSITION | TOPIX PHARMACEUTICALS, INC. | 2024-03-07 | — | — | US | disclosed |
| US-4797223-A | ANIONIC, CATIONIC OR NONIONIC SURFACTANTS | ROHM AND HAAS COMPANY (US) | 1989-01-10 | — | — | US | disclosed |
| US-4647309-A | Waterborne firm coating for temporary protection of parts, providing controlled lubrication during assembly | ASHLAND OIL, INC. (US) | 1987-03-03 | — | — | US | disclosed |
| US-4612054-A | Carbodiimide driers for resin coating compositions | ASHLAND OIL, INC. (US) | 1986-09-16 | — | — | US | disclosed |
| US-4479981-A | CORROSION RESISTANCE | ASHLAND OIL, INC. (US) | 1984-10-30 | — | — | US | disclosed |
| US-4444803-A | Water-borne soft coating compositions and processes therefor | ASHLAND OIL, INC. (US) | 1984-04-24 | — | — | US | disclosed |
| US-4444802-A | WAXES, ESTERS, ALCOHOLIC COUPLING SOLVENT | ASHLAND OIL, INC. (US) | 1984-04-24 | — | — | US | disclosed |
| EP-0093324-A1 | Water-borne firm coating compositions and processes therefor | ASHLAND OIL, INC. (US) | 1983-11-09 | — | — | EP | disclosed |
| EP-0093323-A1 | Water-borne hard coating compositions and processes therefor | ASHLAND OIL, INC. (US) | 1983-11-09 | — | — | EP | disclosed |
| EP-0093388-A2 | Water-borne soft coating compositions and processes therefor | ASHLAND OIL, INC. (US) | 1983-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108556-A1 | SCAR TREATMENT COMPOSITION | MMP1, MMP8, PLAT | CA1 4640/4885CA2 3856/4885CA9 4021/4885 |
| US-20240075112-A1 | SCAR TREATMENT COMPOSITION | MMP1, MMP8, MMP2 | CA1 4638/4885CA2 4072/4885CA9 3395/4885 |
| US-20240238303-A1 | LARGE-CONDUCTANCE POTASSIUM CHANNEL MODULATORS, COMPOSITIONS THEREOF, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF | KCNN2, KCNN1, KCNN3 | CA1 731/4885CA2 229/4885CA9 1736/4885 |
| US-12016939-B2 | Skin treatment methods and compositions for transdermal delivery of active agents | CUTA, MMP1, TYR | CA1 4585/4885CA2 2211/4885CA9 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.